青岛海尔生物医疗股份有限公司的主营业务是公司以创用户最佳体验，面向医药生物企业、高校科研机 构等生命科学用户和医院、疾控、血站、基层公卫等医疗卫生用户，已形成生命科学和医疗创新两大板 块，提供以智慧实验室、数字医院、智慧公共卫生、智慧用血等为代表的数字场景综合解决方案。公司 的主要产品是低温保存箱、自动化生物样本存储库、全自动细胞培养工作站、自动化液氮罐、生物安全 柜、离心机、二氧化碳培养箱、高压灭菌器、恒温恒湿箱、恒温干燥箱、生化培养箱、环境测试箱、人 工气候箱、无菌隔离器、程序降温仪、航空温控集装箱、全自动冻干机、过氧化氢消毒机、独立通气笼 具、可控冻融系统、医用冷藏箱、智能贴签机、智能分拣机、统排机、智能配液机器人、智能静配流水 线、自动发药机、全自动包药机等院内自动化用药产品。2022年公司获得国家级博士后科研工作站、中 国工业大奖、中国科技产业化促进会科学技术奖一等奖、山东省科技进步一等奖等奖项，获批山东省工 业领域优秀数据安全解决方案，公司在生命科学和医疗创新领域科创实力不断提升。目前，公司产品及 解决方案已应用于全球130余个国家和地区，并与世界卫生组织（WHO）、联合国儿童基金会 （UNICE ...

作为盈康一生旗下企业，海尔生物通过"AI+大模型应用"战略，全面赋能生命科学与医疗创新场景，标 志着其从硬件制造商向数智化场景方案服务商转型的加速推进。 聚焦场景落地：AI技术重塑医疗效率与安全 依托AI大模型与垂直场景数据的深度融合，海尔生物在多个医疗场景实现突破。 文/杨燕 在第91届中国国际医疗器械博览会（CMEF）上，海尔生物以"AI在海尔 因AI盈康"为主题，重磅发布 《中国生物样本库行业创新发展白皮书》，并推出搭载AI技术的第四代生物样本库"生命方舟"、恒昀温 湿双控医用冷藏箱等创新成果，全面展示其在AI技术驱动下的医疗生态新图景。 公司还正式发布了新一代的"AI+大模型应用"全面战略，彰显其在生命科学领域的数智化领导力。 顾向炜强调，AI的应用并非单纯的功能叠加，而是通过智能体技术重构"产品-场景-服务"的价值链条， 推动方案从"功能型"向"数智型"代际跨越。 重塑生态共建：从技术领先到标准引领 自打破国外垄断、突破超低温核心技术以来，海尔生物一直致力于以高端技术推动行业高质量发展，并 以技术创新驱动行业标准体系建设。 自2006年至今，海尔生物已连续三次牵头制定或修订《低温保存箱》国家标准，并 ...

Group 1 - TÜV Rheinland awarded Haier Biomedical the first EU MDR certificate for medical low-temperature storage devices, indicating compliance with international standards for safety and effectiveness [1] - The certification allows Haier Biomedical's products to enter the EU market and accelerates registration processes in Southeast Asia, the Middle East, and Africa [1] - The demand for medical low-temperature storage devices is increasing due to advancements in life sciences and biotechnology, driving market growth [1] Group 2 - The acquisition of the EU MDR certificate reflects Haier Biomedical's international innovation strategy and commitment to product quality and compliance [2] - As of the end of 2024, Haier Biomedical has obtained over 400 overseas certifications, including more than 200 EU CE certifications and 70 US FDA certifications [2] - The company emphasizes self-innovation and high standards to enhance its international market presence [2]

Core Insights - The integration of AI in healthcare is transforming the industry, with significant advancements showcased at the 91st China International Medical Equipment Fair (CMEF) [2][4][10] - The Chinese government is actively supporting the innovation and development of medical devices through policy reforms and financial incentives, including a special bond of 148 billion yuan [2][15] - Domestic companies are making strides in high-end medical equipment, with products that enhance precision and accessibility in healthcare [10][15][22] Group 1: AI and Medical Technology - The AI-driven medical models, such as Mindray's "Qiyuan" critical care model, can integrate patient data and provide treatment suggestions within five seconds, already implemented in several top-tier hospitals [4][10] - Haier Biomedical has launched an AI strategy with its "Kuidou" sample library model, focusing on intelligent management of biological samples [4][6] - The emergence of AI-powered solutions in blood sugar management, remote emergency care, and imaging diagnostics is pushing the medical field from "assistance" to "autonomy" [4][10] Group 2: Innovations in Medical Devices - The introduction of the "Newton 3D" intraoperative CT and surgical robot by GeRui Technology showcases advancements in precision surgery, offering real-time 3D imaging and navigation for complex procedures [13] - The ZAP-X radiation surgery robot, featuring a unique self-shielding design, is aimed at improving the safety and precision of radiation therapy for brain and head-neck tumors [15] - The launch of innovative non-invasive respiratory devices, such as the SyncFree algorithm-based respiratory machine by Yuyue Medical, highlights the shift towards home healthcare solutions [20] Group 3: Market Trends and Consumer Needs - The demand for home healthcare solutions is rising, particularly for chronic conditions like COPD and OSA, with projections indicating significant increases in patient numbers by 2025 [16][18] - The domestic hearing aid market is experiencing a transformation, with local products now competing with foreign brands due to advancements in technology and affordability [20] - The overall vitality of the domestic medical device industry is evident, as it continues to evolve towards high-quality development and innovation [22]

Core Viewpoint - Qingdao Haier Biomedical Co., Ltd. announced that its actual controller's concerted action party, Haichuangzhi, has completed a share buyback plan, acquiring 5,729,305 shares, which is 1.8% of the total share capital, for a total amount of 181.84 million yuan [2][8]. Group 1 - The share buyback plan was initiated on January 8, 2025, with a target to purchase between 100 million yuan and 200 million yuan within six months [2][6]. - As of April 10, 2025, Haichuangzhi has completed the buyback, with an average purchase price of 31.74 yuan per share [7][8]. - Following the buyback, Haichuangzhi holds 8,675,900 shares, representing 2.73% of the total share capital, while Haier Group and its concerted action parties collectively hold 141,371,022 shares, or 44.46% of the total [8]. Group 2 - The purpose of the buyback is to enhance investor confidence based on the belief in the company's future development and long-term investment value [4]. - The buyback was executed through a centralized bidding method on the Shanghai Stock Exchange [7]. - The buyback plan did not set a price range and was subject to market conditions [7].

证券代码：688139 证券简称：海尔生物 公告编号：2025-031 2025 年 4 月 10 日，公司收到实际控制人的一致行动人海创智《关于增持青 岛海尔生物医疗股份有限公司股份结果的通知》，现将有关情况公告如下： 1 一、增持主体的基本情况 （一）增持主体的名称：青岛海创智管理咨询企业（有限合伙） （二）本次增持前，海创智持有公司股份 2,946,595 股，占公司总股本的 0.93%，海尔集团公司通过其控制的青岛海尔生物医疗控股有限公司和青岛海创 睿股权投资基金中心（有限合伙）分别持有公司股份 100,591,463 股和 32,103,659 股，分别占公司总股本的 31.64%和 10.10%。海尔集团公司及其一致 行动人合计持有公司股份 135,641,717 股，占公司总股本的 42.66%。 青岛海尔生物医疗股份有限公司 关于实际控制人的一致行动人增持公司 股份结果的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 20 ...

二〇二五年四月 北京市中伦律师事务所 北京市中伦律师事务所 关于青岛海尔生物医疗股份有限公司 实际控制人之一致行动人增持公司股份的 专项核查意见 对于本核查意见，本所律师作出如下声明： 1. 本所律师在工作过程中，已得到海尔生物的保证：即公司业已向本所律 师提供了本所律师认为制作本核查意见所必需的原始书面材料、副本材料、扫描 件、复印件和口头证言，其所提供的文件和材料是真实、准确和完整的，且无隐 瞒、虚假和重大遗漏之处。 2. 本所律师依据本核查意见出具之日以前已经发生或者存在的事实和《公 司法》《证券法》等国家现行法律、法规、规范性文件和中国证券监督管理委员 会（以下简称"中国证监会"）的有关规定发表法律意见。 关于青岛海尔生物医疗股份有限公司 实际控制人之一致行动人增持公司股份的 专项核查意见 致：青岛海尔生物医疗股份有限公司 北京市中伦律师事务所接受委托就青岛海尔生物医疗股份有限公司（以下简 称"海尔生物"或"公司"）实际控制人海尔集团公司（以下简称"海尔集团"） 之一致行动人青岛海创智管理咨询企业（有限合伙）（以下简称"海创智"）增持 海尔生物股份（以下简称"本次增持"）的相关事宜出具《北京市中伦律师 ...

当前，AI与医疗健康的融合已从技术探索迈向规模化应用，推动行业进入数智化转型新阶段。4月8日-11日， 在 第91届中国国际医疗器械(春季)博览会 (以下简称"CMEF") 上，盈康一生旗下 海尔生物医疗 以"Ai在海 尔，因Ai盈康 "为主题，携多个"AI+智慧场景"和15大明星产品重磅亮相。 从AI+智慧样本库、AI+智慧科研，到AI+智慧用药、AI+智慧疫苗接种、AI+智慧血液管理，海尔生物医疗以新 科技、新场景、新生态，不仅为行业带来一场生命科学与医疗创新+AI的生态成果盛宴，也为产业重构带来了 未来想象空间。 # 逐"绿"向"智"，构建生命科学研究新范式 在可持续发展与智能化转型浪潮下，绿色科技与AI技术正重构生命科学产业范式，加速推进全链条数智化进 程。此次CMEF上，海尔生物医疗立足 样本高质量保藏管理和医院临床干细胞研究 ，为高校、科研机构、医 院、药企等用户带来了 一站式样本库全生命周期解决方案、可按需定制的智慧实验室场景解决方案 等，助力 生命科学研究和前沿医学进步。 在AI+智慧样本库展区，海尔生物医疗立足高质量样本库建设需求，带来了 一站式样本库全生命周期解决方案 和4大首发新品。 基 ...

Investment Rating - The report maintains a "Recommended" rating for Haier Biomedical (688139) with a target price of 42 yuan [2][8]. Core Views - The company reported a total revenue of 2.284 billion yuan for 2024, reflecting a slight increase of 0.13% year-on-year, while the net profit attributable to shareholders decreased by 9.71% to 367 million yuan [2][4]. - In Q4 2024, revenue accelerated to 502 million yuan, marking a growth of 10.40%, and net profit attributable to shareholders increased by 17.63% to 57 million yuan [2][4]. - The report highlights that the company is gradually returning to normal operations, with improving order growth despite challenges in the external environment [8]. Financial Summary - The projected total revenue for 2025 is estimated at 2.630 billion yuan, with a year-on-year growth rate of 15.2% [4]. - The net profit for 2025 is expected to reach 442 million yuan, representing a growth of 20.6% compared to 2024 [4]. - The company's gross margin for 2024 was reported at 47.99%, with an adjusted figure of 50.43% when accounting for changes in accounting policies [8]. Business Segment Performance - The Life Sciences segment achieved a revenue of 1.094 billion yuan in 2024, reflecting a growth of 6.14% [8]. - The Medical Innovation segment reported a revenue of 1.180 billion yuan, down 4.91% year-on-year, primarily due to disruptions from solar vaccine projects [8]. - Domestic revenue grew by 4.75% to 1.559 billion yuan, while overseas revenue decreased by 8.73% to 715 million yuan, although it showed signs of recovery in Q4 [8]. Future Outlook - The report anticipates that the net profit for 2025-2027 will be 440 million, 540 million, and 640 million yuan respectively, with corresponding growth rates of 20.6%, 23.1%, and 18.3% [8]. - The overall valuation of the company is estimated at 13.3 billion yuan, corresponding to the target price of approximately 42 yuan [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance is gradually stabilizing, and it is expected to return to a good growth trajectory in 2025 [1][5] - The life sciences segment is experiencing continuous innovation and growth, with new product categories accelerating [5] - The medical innovation segment is recovering, with strong growth in hospital automation and public health services [5] - The company has a clear advantage in its niche areas and is actively expanding new business lines, with new orders growing rapidly [5] Financial Summary - Revenue for 2022 was 2,864.04 million, with a year-on-year growth of 34.72%. In 2023, revenue decreased to 2,280.90 million, a decline of 20.36%. It is projected to increase to 2,594.89 million in 2025, reflecting a growth of 13.62% [2] - Net profit attributable to the parent company was 600.79 million in 2022, down 28.90% year-on-year. It is expected to recover to 408.08 million in 2025, with a growth of 11.31% [2] - The gross margin for 2024 is projected to be 47.99%, with a slight decline from previous years [2] - The company’s earnings per share (EPS) for 2025 is expected to be 1.28 yuan, with a price-to-earnings (PE) ratio of 24.95 [2][5] Segment Performance - The life sciences segment generated revenue of 1,094 million in 2024, a year-on-year increase of 6.14%, driven by new product launches [5] - The medical innovation segment's revenue was 1,180 million in 2024, a decrease of 4.91%, but showing signs of recovery in automation and digital services [5] Future Projections - The company is expected to achieve net profits of 4.08 million, 4.83 million, and 5.64 million for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.28, 1.52, and 1.77 yuan [5][6]